Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies.

ABSTRACT: Integrins are critical intermediaries in a wide spectrum of cancer cell activities and thus represent a highly attractive target in oncology therapy. Nonetheless, successful exploitation of anti-integrin therapeutics has proven challenging to date for cancer patients. In this review, we will focus on cilengitide, an RGD pentapeptide inhibitor of α V integrins. Although several integrin inhibitors are under clinical evaluation, cilengitide is the most clinically advanced and is emerging as a prototype for this class of anticancer therapy. A foundation of encouraging preclinical studies led to a well-designed clinical development plan that culminated in a pivotal phase III study of cilengitide in combination with radiation therapy and temozolomide chemotherapy for newly diagnosed glioblastom

SUBMITTER: Reardon DA 

PROVIDER: S-EPMC3411133 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature